BRMS1 downregulation is a poor prognostic biomarker in anaplastic thyroid carcinoma patients

Background Anaplastic thyroid carcinoma (ATC) is the most aggressive cancer in humans with no optimal treatment strategy available. The molecular mechanisms of ATC remain unclear. The aim of this study was to investigate the prognostic value and role of BRMS1 in the progression of ATC.